Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this cohort study is to estimate the incidence of AD in the first-degree relatives of patients with AD. The main questions it aims to answer are:
This study is a prospective cohort study focusing on the first-degree relatives of patients with Alzheimer's disease (AD). Multiple methods including the neuropsychiatric assessment battery, magnetic resonance imaging (MRI) and fluid biomarkers (blood and urine) are used to estimate the longitudinal changes of the participants at high risk of AD. Besides, a structured questionnaire is designed to investigate how environmental, behavioral and other factors influence the incidence of AD. This study is of great significance in establishing novel guidelines for the prevention and treatment of dementia suitable for Chinese population, and for clinicians to predict the risk of AD in first-degree relatives.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of cognitive impairment at 5 years | Number of participants who covert to AD or mild cognitive impairment (MCI) will be recorded to calculate the incidence. | 5 years |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in Mini-Mental State Examination (MMSE) at 5 years | MMSE is a brief screening instrument used to assess cognitive function (orientation, memory, attention, ability to name objects, follow verbal/written commands, write a sentence, and copy figures) in elderly participants. Total score ranges from 0 to 30; lower score indicates greater disease severity. | 5 years |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in Blood concentration of Phosphorylated Tau (p-tau) at 5 years | Blood p-tau 181 and p-tau 217 at baseline will be tested. The higher blood p-tau is a strong predictor for AD. | 5 years |
| Change From Baseline in Blood Concentration of Amyloid β (Aβ) at 5 years |
Inclusion Criteria:
Exclusion criteria:
Individuals will be excluded if they have:
Not provided
Not provided
Not provided
The study population is the first-degree, cognition-preserved relatives (including parents, children and siblings of the same father and mother) of patients with AD
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Gang Wang, MD, PhD | Contact | 086-021-64370045 | wg11424@rjh.com.cn |
| Name | Affiliation | Role |
|---|---|---|
| Gang Wang, MD, PhD | Ruijin Hospital | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Ruijin Hospital, Shanghai Jiao Tong University School of Medicine | Recruiting | Shanghai | Shanghai Municipality | 200025 | China |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 30867271 | Background | Cannon-Albright LA, Foster NL, Schliep K, Farnham JM, Teerlink CC, Kaddas H, Tschanz J, Corcoran C, Kauwe JSK. Relative risk for Alzheimer disease based on complete family history. Neurology. 2019 Apr 9;92(15):e1745-e1753. doi: 10.1212/WNL.0000000000007231. Epub 2019 Mar 13. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000544 | Alzheimer Disease |
| D003704 | Dementia |
| D019636 | Neurodegenerative Diseases |
| D060825 | Cognitive Dysfunction |
| D019965 | Neurocognitive Disorders |
| ID | Term |
|---|---|
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D024801 | Tauopathies |
Not provided
Not provided
Not provided
Not provided
Not provided
Whole blood (3-4 ml) of all participants will be collected at baseline and stored at -80°C.
| Change From Baseline in Montreal cognitive assessment-Basic (MoCA) at 5 years | MoCA is a brief screening instrument used to assess cognitive function (orientation, memory, attention, ability to name objects, follow verbal/written commands, write a sentence, and copy figures) in elderly participants. Total score ranges from 0 to 30; lower score indicates greater disease severity. | 5 years |
| Change From Baseline in Boston naming test (BNT) at 5 years | MoCA is a screening instrument used to assess object naming function. The total score ranges from 0 to 30, with lower scores indicating greater disease severity. | 5 years |
| Change From Baseline in the auditory verbal learning test (AVLT) at 5 years | AVLT is a screening instrument used to assess the function of memory. The score in long-term memory (N5) ranges from 0 to 12, with lower scores indicating greater disease severity. | 5 years |
| Change From Baseline in trail making test (TMT) at 5 years | AVLT is a screening instrument used to assess the executive function. Time consumed is recorded as the result, with higher scores indicating greater disease severity. | 5 years |
| Change From Baseline in Geriatric Depression Scale (GDS) at 5 years | GDS is a neuropsychological scale used to assess the level of depression. The total score ranges from 0 to 30, with higher scores indicating greater disease severity. | 5 years |
| Change From multi-modal MRI neuroimaging at 5 years | Evaluation of multimodal MRI, including high-resolution structural T1 imaging, functional MRI, diffusion tensor imaging and quantitative susceptibility mapping. | 5 years |
Blood Aβ40 and Aβ42 at baseline will be tested. The decreased blood Aβ42/40 ratio is a strong predictor for AD. |
| 5 years |
| D001523 |
| Mental Disorders |
| D003072 | Cognition Disorders |